罗欣药业(002793.SZ)：子公司拟将乐康制药100%股权转让给临沂君康

Core Viewpoint - The company has decided to terminate the public listing for the sale of its subsidiary, LeKang Pharmaceutical, due to a lack of qualified buyers after one year and will instead transfer the ownership to LinYi JunKang for 62.5 million RMB [1] Group 1: Company Actions - The company held its 19th meeting of the 5th Board of Directors on November 18, 2024, where it approved the proposal to publicly list the sale of its subsidiary's equity [1] - The company’s subsidiary, Shandong LuoXin, will transfer 100% of its stake in LeKang Pharmaceutical to LinYi JunKang for a consideration of 62.5 million RMB [1] - Following the transfer, Shandong LuoXin will no longer hold any equity in LeKang Pharmaceutical, which will be excluded from the company’s consolidated financial statements [1] Group 2: Financial Implications - Prior to the transfer, Shandong LuoXin provided a loan of 2.8 million RMB to LeKang Pharmaceutical, which remains outstanding with a total amount of 2.8005 million RMB including interest [1] - The outstanding loan amount is expected to be settled by October 26, 2026, as confirmed by all parties involved [1]